PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

Pfizer Inc. delivered a 17% total return since early November, but fundamentals lag and valuation isn’t compelling. Read more on PFE stock here.

It's worth taking a second look at the healthcare giant.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Pfizer is one of the world's largest pharmaceutical companies. It has a long history of navigating the competitive and technically complex industry. Pfizer's stock has lost half its value since late ...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1.